Skip to content

Study on the Safety and Efficacy of Esmolamine in General Anesthesia After Cesarean Section

Study on the Safety and Efficacy of Esmolamine in General Anesthesia After Cesarean Section

Status
Active, not recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2000031819
Enrollment
Unknown
Registered
2020-04-11
Start date
2020-05-01
Completion date
Unknown
Last updated
2020-04-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pregnancy waiting for delivery

Interventions

experimental group:Intravenous injection of esketamine 0.5mg / kg.

Sponsors

The First Affiliated Hospital of Wannan Medical College
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
20 Years to 40 Years

Inclusion criteria

Inclusion criteria: 1) parturient delivered by cesarean section; 2) Maternal aged 20 - 40 years; 3) gestational age >= 28 weeks = 10; 5) pregnancy without assisted reproductive means; 6) first parturient. 7) the subjects and their families voluntarily signed informed consent.

Exclusion criteria

Exclusion criteria: 1) patients with severe cardiovascular history such as myocardial ischemia, heart failure and arrhythmia), patients with cardiac pain (unstable angina pectoris) caused by insufficient blood supply of coronary arteries, or patients with myocardial infarction in the last 6 months; 2) patients with mental system diseases (schizophrenia, mania, bipolar abnormality, insanity, etc.), drug history and cognitive impairment; 3) patients with a history of asthma; 4) the good Ma score of the patients with respiratory tract management difficulties was grade IV; 5) AST and ALT > 2.5 x ULN, TBII >= 1.5 x ULN; urea or urea nitrogen > 1.5 x ULN, were higher than the upper limit of normal value in patients with severe heart, lung, liver and kidney disease or hepatorenal dysfunction before operation. 6) patients with abnormal blood coagulation PT or INR >= 1.5 x ULN, APTT >= 1.5 x ULN; 7) anemia or thrombocytopenia, Hb 100kg, height 180cm.

Design outcomes

Primary

MeasureTime frame
MAP, HR, CO, SvR and LCW;Propofol consumption;Awakening score record;Neonatal Apgar score;Cord blood gas analysis;Separated state scale CADSS;VAS score;

Secondary

MeasureTime frame
Nausea, headache, dizziness, blurred vision;

Countries

China

Contacts

Public ContactChen Yongquan

The First Affiliated Hospital of Wannan Medical College

402697510@qq.com+86 18895382179

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026